Tetraneuron SL - Álvaro GarcíaSpanish Tetraneuron secures financing to advance its E2F4DN-based Alzheimer’s gene therapy, restoring neuronal homeostasis and halting disease progression in Europe.
Tag Archive for: Alzheimer’s
adobe.stock.com - ipopbaNovo Nordisk’s semaglutide has failed to reduce the cognition deficit in two Phase III Alzheimer’s trials, dimming GLP-1 hopes. Anti-amyloid and combination therapies remain key for slowing decline.
stock.adobe.com/Sadushi Melatonin shows promise in Alzheimer’s treatment by restoring circadian rhythms and reducing neurodegenerative symptoms, researchers have demonstrated in a groundbreaking study.
ForbionBritish company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. Ltd. in exchange for the development and marketing rights to the low-molecular-weight inflammation blocker FXS6837.
Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
AC Immune SASwiss AC Immune and its partner Janssen Pharmaceuticals Inc have been granted FDA Fast Track Designation for their active anti-pTau vaccine ACI-35.030/JNJ-2056 to treat Alzheimer’s disease.
AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
Alzheimer’s specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimer’s diseas